To hear about similar clinical trials, please enter your email below
Trial Title:
Uncovering Potential Breast Cancer Biomarkers Amp; Possible Drug Targets Using Advanced Quantitative Mass Spectrometry
NCT ID:
NCT01619514
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Retrospective
Summary:
The purpose of this study is to evaluate the use of advanced quantitative mass
spectometry (Super SILAC) as a discovery platform to uncover novel protein biomarkers in
tumor and to compare the protein profile between different subtypes of breast cancer (ER
positive, HER2 positive, triple negative). A maximum of 100 breast tumor specimens will
be obtained from the NUHS Tissue repository, comprising approximately equal proportion of
ER positive, HER2 positive, and triple negative tumors. Samples will be analyzed using
advanced Mass Spectrometry (Super SILAC) as a discovery platform to identify novel
protein biomarkers that may be important in cancer. DNA and RNA will also be extracted
from tumor samples for correlative analysis with the proteomics data. Genomics and
proteomics data will be correlated with clinical data including treatment response and
survival data. Importance of proposed research to science or medicine:Identification of
tumor biomarkers may allow better prognostication, follow-up, and selection of treatment
for cancer patients in the future. Potential benefits and risks: No direct benefit to the
patient. Risk to the subjects is minimal as there is no direct patient contact, and
analysis is done on previously donated tumor samples. Patients have previously provided
consent to donate their samples for research into the NUHS Tissue Repository.
Novel tumor biomarkers that determine tumor biology, including prognosis and treatment
sensitivity, may be detectable using the novel advanced quantitative mass spectromy
method (Super SILAC). Different subtypes of breast cancers will have different proteomic
profiles analyzed using super SILAC.
Criteria for eligibility:
Study pop:
Tumor specimens that have been stored in the NUHS tissue repository will be retrieved
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Patients with breast cancer
Gender:
Female
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Nationa University Hospital
Address:
City:
Singapore
Country:
Singapore
Status:
Recruiting
Contact:
Last name:
Soo Chin Lee, MBBS, MRCP
Phone:
+65 6779 5555
Email:
Soo_Chin_Lee@nuhs.edu.sg
Investigator:
Last name:
Soo Chin Lee, MBBS, MRCP
Email:
Principal Investigator
Start date:
March 2012
Lead sponsor:
Agency:
National University Hospital, Singapore
Agency class:
Other
Source:
National University Hospital, Singapore
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT01619514
